

Teus van Laar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/42368/publications.pdf>

Version: 2024-02-01

104
papers

5,063
citations

145106

33
h-index

107981

68
g-index

110
all docs

110
docs citations

110
times ranked

5516
citing authors

#	ARTICLE	IF	CITATIONS
1	The Intraoperative Microlesion Effect Positively Correlates With the Short-Term Clinical Effect of Deep Brain Stimulation in Parkinson's Disease. <i>Neuromodulation</i> , 2023, 26, 459-465.	0.4	9
2	Serendipitous Stimulation of Nucleus Basalis of Meynertâ€™The Effect of Unintentional, Long-Term High-Frequency Stimulation on Cognition in Parkinsonâ€™s Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 337.	1.0	1
3	Self-Reported Visual Complaints in People with Parkinsonâ€™s Disease: A Systematic Review. <i>Journal of Parkinson's Disease</i> , 2022, 12, 785-806.	1.5	8
4	Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment. <i>Movement Disorders</i> , 2022, 37, 713-723.	2.2	27
5	Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 345-371.	0.9	8
6	Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study. <i>Aging Brain</i> , 2022, 2, 100039.	0.7	15
7	Letter to the editor, â€œValidation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medicationsâ€. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 99-100.	1.1	3
8	Intraoperative Quantification of MDS-UPDRS Tremor Measurements Using 3D Accelerometry: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2275.	1.0	8
9	Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 642-650.	2.2	41
10	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 79-85.	1.1	39
11	Electrical stimulation of the nucleus basalis of meynert: a systematic review of preclinical and clinical data. <i>Scientific Reports</i> , 2021, 11, 11751.	1.6	17
12	Treatment of subcutaneous nodules after infusion of apomorphine; a biopsy-controlled study comparing 4 frequently used therapies. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 38-40.	1.1	1
13	Early Factors for Predicting Discontinuation to Subcutaneous Apomorphine Infusion in Parkinsonâ€™s disease: A Prospective Analysis of the Thai Apomorphine Registry. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 146-151.	1.1	6
14	Enhanced arm swing improves Parkinsonian gait with EEG power modulations resembling healthy gait. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 96-101.	1.1	9
15	Systematic analysis of PINK1 variants of unknown significance shows intact mitophagy function for most variants. <i>Npj Parkinson's Disease</i> , 2021, 7, 113.	2.5	6
16	Postural and gait symptoms in de novo Parkinson's disease patients correlate with cholinergic white matter pathology. <i>Parkinsonism and Related Disorders</i> , 2021, 93, 43-49.	1.1	6
17	Effectiveness of ReSET; a strategic executive treatment for executive dysfunctioning in patients with Parkinsonâ€™s disease. <i>Neuropsychological Rehabilitation</i> , 2020, 30, 67-84.	1.0	11
18	Abnormal pattern of brain glucose metabolism in Parkinsonâ€™s disease: replication in three European cohorts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 437-450.	3.3	54

#	ARTICLE	IF	CITATIONS
19	Pre-Movement Cortico-Muscular Dynamics Underlying Improved Parkinson Gait Initiation after Instructed Arm Swing. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1675-1693.	1.5	12
20	Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 935-944.	1.5	8
21	Multicenter Validation of Metabolic Abnormalities Related to <scp>PSP</scp> According to the <scp>MDSâ€PSP</scp> Criteria. <i>Movement Disorders</i> , 2020, 35, 2009-2018.	2.2	18
22	Long-Term Patient-Reported Outcome of Radiofrequency Thalamotomy for Tremor. <i>Stereotactic and Functional Neurosurgery</i> , 2020, 98, 187-192.	0.8	8
23	Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinsonâ€™s disease patients for the identification and validation of biomarkers for Parkinsonâ€™s disease subtypes, progression and pathophysiology. <i>BMC Neurology</i> , 2020, 20, 245.	0.8	17
24	Optimal Parameters of Deep Brain Stimulation in Essential Tremor: A Meta-Analysis and Novel Programming Strategy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1855.	1.0	10
25	A <scp>Largeâ€Scale</scp> Full <scp><i>GBA1</i></scp> Gene Screening in Parkinson's Disease in the Netherlands. <i>Movement Disorders</i> , 2020, 35, 1667-1674.	2.2	41
26	Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinsonâ€™s disease management in developing countries. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 523-537.	1.4	7
27	Introduction: The Gut-Brain Axis in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, S279-S279.	1.5	2
28	Accuracy of Intraoperative Computed Tomography in Deep Brain Stimulationâ€™A Prospective Noninferiority Study. <i>Neuromodulation</i> , 2019, 22, 472-477.	0.4	18
29	rTMS treatment of visual hallucinations using a connectivity-based targeting method - A case study. <i>Brain Stimulation</i> , 2019, 12, 1622-1624.	0.7	6
30	Randomized Delayed-Start Trial of Levodopa in Parkinsonâ€™s Disease. <i>New England Journal of Medicine</i> , 2019, 380, 315-324.	13.9	225
31	Retinal layers in Parkinson's disease: A meta-analysis of spectral-domain optical coherence tomography studies. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 40-49.	1.1	91
32	[¹⁸ F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer. <i>Movement Disorders</i> , 2019, 34, 924-926.	2.2	20
33	Oscillatory activity and cortical coherence of the nucleus basalis of Meynert in Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 102-106.	1.1	11
34	Effect of Pharmacist-Led Interventions on (Non)Motor Symptoms, Medication-Related Problems, and Quality of Life in Parkinson Disease Patients: A Pilot Study. <i>Clinical Neuropharmacology</i> , 2018, 41, 14-19.	0.2	11
35	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 71-84.	1.5	12
36	Substituting the Target After Unsatisfactory Outcome of Deep Brain Stimulation in Advanced Parkinsonâ€™s Disease: Cases From the NSTAPS Trial and Systematic Review of the Literature. <i>Neuromodulation</i> , 2018, 21, 527-531.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Deep Brain Stimulation for Essential Tremor: A Comparison of Targets. <i>World Neurosurgery</i> , 2018, 110, e580-e584.	0.7	38
38	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2018, 17, 749-759.	4.9	203
39	Cutaneous adverse drug reaction after apomorphine infusion, possibly caused by a systemic type IV hypersensitivity reaction to sodium metabisulfite: Report of 2 cases. <i>Contact Dermatitis</i> , 2018, 79, 316-318.	0.8	13
40	Successful treatment of intractable visual hallucinations with 5-HT2A antagonist ketanserin. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224340.	0.2	4
41	Graphical Tasks to Measure Upper Limb Function in Patients With Parkinson's Disease: Validity and Response to Dopaminergic Medication. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2017, 21, 283-289.	3.9	21
42	Objective Versus Subjective Measures of Executive Functions: Predictors of Participation and Quality of Life in Parkinson Disease?. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 2181-2187.	0.5	20
43	Adaptive DBS in a Parkinson's patient with chronically implanted DBS: A proof of principle. <i>Movement Disorders</i> , 2017, 32, 1253-1254.	2.2	73
44	A Guideline for Parkinson's Disease Nurse Specialists, with Recommendations for Clinical Practice. <i>Journal of Parkinson's Disease</i> , 2017, 7, 749-754.	1.5	39
45	Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 33-38.	1.1	34
46	FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. <i>Movement Disorders</i> , 2017, 32, 1482-1486.	2.2	67
47	Environmental exposure to pesticides and the risk of Parkinson's disease in the Netherlands. <i>Environment International</i> , 2017, 107, 100-110.	4.8	121
48	The role and structure of the multidisciplinary team in the management of advanced Parkinson's disease with a focus on the use of levodopa–carbidopa intestinal gel. <i>Journal of Multidisciplinary Healthcare</i> , 2017, Volume 10, 13-27.	1.1	17
49	Unmet needs in Parkinson's disease: New horizons in a changing landscape. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S2-S8.	1.1	19
50	The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S22-S27.	1.1	9
51	Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therapy. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S49-S55.	1.1	31
52	How Many Patients would Benefit from Steering Technology for Deep Brain Stimulation?. <i>Brain Stimulation</i> , 2016, 9, 144-145.	0.7	10
53	Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 35-40.	1.1	40
54	Mental slowness in patients with Parkinson's disease: Associations with cognitive functions?. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 844-852.	0.8	26

#	ARTICLE	IF	CITATIONS
55	Cognitive and psychiatric outcome 3 years after globus pallidus pars interna or subthalamic nucleus deep brain stimulation for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 90-95.	1.1	36
56	Effect of pharmacist-led interventions on motor symptoms in Parkinson's patients: A pilot study. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e27-e28.	1.1	0
57	Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 17-22.	1.1	63
58	Effect of pharmacist-led interventions on motor symptoms in Parkinson's patients: A pilot study. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e87-e88.	1.1	0
59	Diepe hersenstimulatie bij de ziekte van Parkinson. , 2016, , 77-83.		0
60	Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EARly Parkinson's disease: the LEAP-study. <i>BMC Neurology</i> , 2015, 15, 236.	0.8	14
61	Effective Delivery of Apomorphine in the Management of Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2015, 38, 89-103.	0.2	48
62	Improved Gait Performance in a Patient With Hereditary Spastic Paraplegia After a Continuous Intrathecal Baclofen Test Infusion and Subsequent Pump Implantation: A Case Report. <i>Archives of Physical Medicine and Rehabilitation</i> , 2015, 96, 1166-1169.	0.5	23
63	Functional (psychogenic) movement disorders associated with normal scores in psychological questionnaires: A case control study. <i>Journal of Psychosomatic Research</i> , 2015, 79, 190-194.	1.2	46
64	Occupational exposure to solvents, metals and welding fumes and risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 635-639.	1.1	20
65	Deep Brain Stimulation in a Dopaminergic Non-responsive Patient With Parkinson's Disease: Case Report and Systematic Review. <i>Brain Stimulation</i> , 2015, 8, 983-985.	0.7	0
66	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease " Clinical practice recommendations. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1023-1030.	1.1	126
67	Extremely low-frequency magnetic field exposure, electrical shocks and risk of Parkinson's disease. <i>International Archives of Occupational and Environmental Health</i> , 2015, 88, 227-234.	1.1	12
68	Lateral and Medial Ventral Occipitotemporal Regions Interact During the Recognition of Images Revealed from Noise. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 678.	1.0	5
69	Occupational exposure to pesticides and endotoxin and Parkinson disease in the Netherlands. <i>Occupational and Environmental Medicine</i> , 2014, 71, 757-764.	1.3	29
70	Long-term Safety of Rivastigmine in Parkinson Disease Dementia. <i>Clinical Neuropharmacology</i> , 2014, 37, 9-16.	0.2	62
71	Clinical Relevance of Pharmacological and Physiological Data in Intrathecal Baclofen Therapy. <i>Archives of Physical Medicine and Rehabilitation</i> , 2014, 95, 2199-2206.	0.5	34
72	A Case-Control Study of the Protective Effect of Alcohol, Coffee, and Cigarette Consumption on Parkinson Disease Risk: Time-Since-Cessation Modifies the Effect of Tobacco Smoking. <i>PLoS ONE</i> , 2014, 9, e95297.	1.1	52

#	ARTICLE	IF	CITATIONS
73	Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. <i>Lancet Neurology</i> , The, 2013, 12, 37-44.	4.9	607
74	Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 501-507.	1.1	99
75	The added value of semimicroelectrode recording in deep brain stimulation of the subthalamic nucleus for Parkinson disease. <i>Neurosurgical Focus</i> , 2013, 35, E3.	1.0	6
76	The treatment of early Parkinson's disease: levodopa rehabilitated. <i>Practical Neurology</i> , 2011, 11, 145-152.	0.5	19
77	Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 428-441.	1.9	61
78	Regional cortical grey matter loss in Parkinson's disease without dementia is independent from visual hallucinations. <i>Movement Disorders</i> , 2011, 26, 142-147.	2.2	48
79	Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 331-334.	2.2	27
80	SCOPAâ€œognition cutoff value for detection of Parkinson's disease dementia. <i>Movement Disorders</i> , 2011, 26, 1881-1886.	2.2	30
81	Lasting visual hallucinations in visual deprivation; fMRI correlates and the influence of rTMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1295-1296.	0.9	16
82	Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 71-72.	1.1	42
83	Attentional and perceptual impairments in Parkinson's disease with visual hallucinations. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 270-274.	1.1	48
84	Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 246-253.	1.9	25
85	Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. <i>Brain</i> , 2009, 132, 2980-2993.	3.7	163
86	Characteristics of dystonia in the 18p deletion syndrome, including a new case. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 880-882.	0.6	22
87	The Effects of Apomorphine on Visual Perception in Patients With Parkinson Disease and Visual Hallucinations. <i>Clinical Neuropharmacology</i> , 2009, 32, 266-268.	0.2	19
88	Postoperative gait deterioration after bilateral subthalamic nucleus stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 2404-2406.	2.2	87
89	Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. <i>Movement Disorders</i> , 2008, 23, 1532-1540.	2.2	33
90	Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. <i>Movement Disorders</i> , 2008, 23, 1906-1912.	2.2	66

#	ARTICLE	IF	CITATIONS
91	Continuous Drug Delivery with Levodopa/Carbidopa Infusion: <i>Review and First Data of a Dutch Cohort</i>. CNS Spectrums, 2008, 13, 11-14.	0.7	0
92	1.IS.3. On-going developments in the use of apomorphine in complex Parkinson's disease (Britannia) Tj ETQq0 0 0 rBT /Overlock 10 Tf 5	1.1	0
93	Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Movement Disorders, 2007, 22, 2430-2435.	2.2	50
94	Fallacious falls. Journal of Neurology, 2005, 252, 1271-1273.	1.8	8
95	Rivastigmine for Dementia Associated with Parkinson's Disease. New England Journal of Medicine, 2004, 351, 2509-2518.	13.9	1,111
96	Levodopa-Induced Response Fluctuations in Patients with Parkinson??s Disease. CNS Drugs, 2003, 17, 475-489.	2.7	36
97	Quick Titration of Pergolide in Cotreatment with Domperidone Is Safe and Effective. Clinical Neuropharmacology, 2001, 24, 177-180.	0.2	15
98	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Movement Disorders, 2001, 16, 197-201.	2.2	111
99	Pharmacokinetic-Pharmacodynamic Relationships of Apomorphine in Patients with Parkinson??s Disease. Clinical Pharmacokinetics, 1999, 37, 257-271.	1.6	66
100	The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study. Movement Disorders, 1998, 13, 52-55.	2.2	19
101	Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion. Movement Disorders, 1998, 13, 176-178.	2.2	20
102	Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. Pharmaceutical Research, 1997, 14, 1804-1810.	1.7	52
103	Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. International Journal of Bio-medical Computing, 1994, 36, 143-150.	0.5	3
104	Population Pharmacokinetics of Apomorphine in Patients with Parkinsonâ€™s Disease. Drug Investigation, 1994, 7, 183-190.	0.6	8